Reprint: Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice1

Altex

Volumn 30, Issue 2, 2013, Pages 227-230

  Leist, Marcel ^a   Hartung, Thomas ^b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; THALIDOMIDE;

ANIMAL EXPERIMENT; ANTISEPSIS; ASTHMA; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; BURN; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; ENDOTOXEMIA; EXPERIMENTAL MOUSE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INJURY; MEDICAL RESEARCH; NEOPLASM; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; TOXICITY TESTING; TOXICOLOGY; TRANSGENIC MOUSE;

EID: 84877614839     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.2013.2.227     Document Type: Review

References (43)

1. Basketter, D. A., Clewell, H., Kimber, I., et al. (2012). A roadmap for the development of alternative (non-Animal) methods for systemic toxicity testing - t4 report. ALTEX 29, 3-91.
2. Blaauboer, B. J., Boekelheide, K., Clewell, H. J., et al. (2012). The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX 29, 411-25.
3. Buras, J. A., Holzmann, B., and Sitkovsky, M. (2005). Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4, 854-65.
4. Christaki, E., Anyfanti, P., and Opal, S. M. (2011). Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 9, 1013-33.
5. De Keyser, J., Sulter, G., and Luiten, P. G. (1999). Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 22, 535-40.
6. Dirnagl, U. And Fisher, M. (2012) REPRINT: International, multicenter randomized preclinical trials in translational stroke research: it is time to act. Stroke 43, 1453-4.
7. Gladstone, D. J., Black, S. E., Hakim, A. M., and Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery (2002). Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33, 2123-36.
8. Gold, L. S., Manley, N. B., Slone, T. H., et al. (2005). Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol Sci 85, 747-808.
9. Hackam, D. G. And Redelmeier, D. A. (2006). Translation of research evidence from animals to humans. JAMA 296, 1731-2.
10. Hartung, T. And Leist, M. (2008). Food for thought ... on the evolution of toxicology and the phasing out of animal testing. ALTEX 25, 91-102.
11. Hartung, T. And McBride, M. (2011) Food for thought ... on mapping the human toxome. ALTEX 28, 83-93.
12. Hartung, T., van Vliet, E., Jaworska, J., et al. (2012). Systems toxicology. ALTEX 29, 119-28.
13. Hartung, T. And Zurlo, J. (2012). Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 29, 251-60.
14. Hartung, T. (2009). Toxicology for the twenty-first century. Nature 460, 208-212.
15. Hartung, T. (2008). Food for thought, on animal tests. ALTEX 25, 3-9.
16. Hasiwa, N., Daneshian, M., Bruegger, P., et al. (2013), Evidence for the detection of non-endotoxin pyrogens (NEPs) by the whole blood monocyte activation test. ALTEX 30, 169-208.
17. Hasiwa, N., Bailey, J., Clausing, P., et al. (2011). Critical evalu ation of the use of dogs in biomedical research and testing in Europe. ALTEX 28, 326-40.
18. Kent, R. B., Emanuel, J. R., Ben Neriah, Y., et al. (1987). Ouabain resistance conferred by expression of the cDNA for a murine Na+, K+-ATPase alpha subunit. Science 237, 901-3.
19. Kilkenny, C., Browne, W. J., Cuthill, I. C., et al. (2010). Improving bioscience research reporting: the ARRIVEguidelines for reporting animal research. PLoS Biol. 29, e1000412.
20. Leist, M., Hartung, T., and Nicotera, P. (2008a). The dawning of a new age of toxicology. ALTEX 25, 103-14.
21. Leist, M., Kadereit, S., and Schildknecht, S. (2008b). Food for thought... on the real success of 3R approaches. ALTEX 25, 17-32.
22. Leist, M., Efremova, L., and Karreman, C. (2010). Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. ALTEX 27, 309-17.
23. Leist, M., Lidbury, B. A., Yang, C., et al. (2012a) Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. ALTEX 29, 373-88.
24. Leist, M., Hasiwa, N., Daneshian, M., and Hartung, T. (2012b). Validation and quality control of replacement alternatives - current status and future challenges. Toxicol Res 1, 8-22.
25. Macleod, M. And van der Worp, H. B. (2010). Animal models of neurological disease: are there any babies in the bathwater? Pract Neurol 10, 312-4.
26. Matthews, R. A. (2008). Medical progress depends on animal models - doesn-t it? J R Soc Med 101, 95-98.
27. Musch, T. I., Carroll, R.G., Just, A., et al. (2006). A broader view of animal research. Br Med J 334, 274.
28. NRC - National Research Council, Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents (2011). Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC, USA: The National Academies Press. http://dels.nationalacademies.org/Report/Animal-Models- Assessing-Countermeasures/13233
29. O'Collins, V. E., Macleod, M. R., Donnan, G. A., et al. (2006). 1,026 experimental treatments in acute stroke. Ann Neurol 59, 467-77.
30. Olson, H., Betton, G., Robinson, D., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56-67.
31. Opal, S. M. And Cross, A. S. (1999). Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 13, 285-97.
32. Rice, J. (2012). Animal models: Not close enough. Nature 484, S9.
33. Rittirsch, D., Hoesel, L.M. And Ward, P.A. (2007). The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81, 137-143.
34. Rossini, G. P. And Hartung, T. (2012). Food for thought ... towards tailored assays for cell-based approaches to toxicity testing. ALTEX 29, 359-72.
35. Savitz, S. I. And Fisher, M. (2007). Future of neuroprotection for acute stroke: in the aftermath of the SAINTtrials. Ann Neurol 61, 396-402.
36. Schlepütz, M., Rieg, A. D., Seehase, S., et al. (2012). Neurally mediated airway constriction in human and other species: a comparative study using precision-cut lung slices (PCLS). PLoS One 7, e47344.
37. Schmidt, M., Raghavan, B., Müller, V., et al. (2010). Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 11, 814-9.
38. Schnerch, A., Cerdan, C., and Bhatia, M. (2010). Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men. Stem Cells 28, 419-30.
39. Sena, E. S., van der Worp, H. B., Bath, P. M., et al. (2010). Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8, e1000344.
40. Seok, J., Warren, H. S., Cuenca, A. G., et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 110, 3507-12.
41. Stebbings, R., Findlay, L., Edwards, C., et al. (2007). "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179, 3325-31.
42. van der Worp, H. B., Howells, D. W., Sena, E. S., et al. (2010). Can animal models of disease reliably inform human studies? PLoS Med 7, e1000245.
43. van der Worp, H. B. And Macleod, M. R. (2011). Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol 51, 449-50.